AstraZeneca (LON:AZN) was downgraded by research analysts at Bryan, Garnier & Co to a “neutral” rating in a research report issued to clients and investors on Thursday.
Several other research analysts have also weighed in on the stock. Barclays reaffirmed an “overweight” rating on shares of AstraZeneca in a research note on Tuesday, October 9th. Shore Capital reissued a “hold” rating on shares of AstraZeneca in a research report on Friday, September 7th. Jefferies Financial Group reissued a “hold” rating and set a GBX 5,800 ($75.79) price target on shares of AstraZeneca in a research report on Friday, October 12th. Credit Suisse Group set a GBX 6,350 ($82.97) price target on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Thursday, August 30th. Finally, Citigroup reissued a “buy” rating and set a GBX 6,200 ($81.01) price target on shares of AstraZeneca in a research report on Tuesday, September 25th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. AstraZeneca presently has a consensus rating of “Hold” and an average target price of GBX 5,831.89 ($76.20).
Shares of AZN stock opened at GBX 6,172 ($80.65) on Thursday. AstraZeneca has a 1-year low of GBX 4,260 ($55.66) and a 1-year high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: Why do company’s buyback their stock?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.